NextPlat Corp. (NASDAQ:NXPL) Sees Significant Decrease in Short Interest

NextPlat Corp. (NASDAQ:NXPL) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totaling 11,956 shares, a decline of 63.8% from the May 31st total of 33,021 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily trading volume, of 31,212 shares, the days-to-cover ratio is presently 0.4 days.

Institutional Investors Weigh In On NextPlat

An institutional investor recently bought a new stake in NextPlat stock. Citadel Advisors LLC acquired a new position in shares of NextPlat Corp. (NASDAQ:NXPL) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned approximately 0.19% of NextPlat at the end of the most recent reporting period. Institutional investors own 1.30% of the company’s stock.

More NextPlat News

Here are the key news stories impacting NextPlat this week:

• Positive Sentiment: Litchfield Hills Research initiated coverage on NextPlat with a Buy rating and a $11.00 price target, suggesting substantial upside potential. Street Insider article
• Positive Sentiment: The analyst sees NextPlat moving toward profitability, forecasting FY2027 EPS of $0.57 and positive quarterly EPS in 2027, which may improve longer-term sentiment. Benzinga article
• Neutral Sentiment: New earnings estimates for FY2026 (-$0.55 EPS) and Q2 2026 (-$0.21 EPS) still indicate losses in the near term, limiting immediate upside. Tickerreport article
• Neutral Sentiment: Short interest data showed a decline earlier in the month, but the most recent update reported 0 shares short, making the data unusual and hard to interpret for trading impact. American Banking News article
• Negative Sentiment: The latest analyst estimates still call for losses through most of 2026, including Q3 2026 EPS of $0.00 and Q4 2026 EPS of $0.07, so investors may remain cautious about near-term earnings power. Benzinga article

NextPlat Price Performance

Shares of NXPL opened at $6.15 on Friday. NextPlat has a 52-week low of $3.38 and a 52-week high of $11.10. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.12 and a current ratio of 2.56. The business’s 50 day moving average price is $6.39 and its two-hundred day moving average price is $5.93. The firm has a market cap of $16.67 million, a PE ratio of -1.42 and a beta of 1.90.

NextPlat (NASDAQ:NXPL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.42) EPS for the quarter. The company had revenue of $9.86 million for the quarter. NextPlat had a negative return on equity of 58.05% and a negative net margin of 23.14%. On average, equities analysts anticipate that NextPlat will post -0.55 EPS for the current year.

Analyst Upgrades and Downgrades

NXPL has been the topic of a number of recent analyst reports. Zacks Research raised NextPlat to a “hold” rating in a research note on Thursday. Weiss Ratings raised shares of NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, Litchfield Hills Research started coverage on shares of NextPlat in a report on Wednesday. They issued a “buy” rating and a $11.00 target price on the stock. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $11.00.

About NextPlat

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.